Here are my final suggestions, prioritized by impact on Q1 acceptance probability:

---

## Tier 1 — High Impact (would significantly increase acceptance odds)

### 1. Add at least one more external validation dataset
Your current external validation uses only MPox-Vision (570 images, 3 classes). A Q1 reviewer will want at least 2 external datasets. Specific datasets to consider:

- **ISIC Archive** (isic-archive.com) — has Monkeypox and Chickenpox subsets; well-established in dermatology AI literature
- **DermNet NZ** (dermnetnz.org) — different image acquisition pipeline than your training sources; has all 4 classes
- **HAM10000** — if you reframe as a general pox/skin lesion transfer learning benchmark
- **MSLD v2.0** (if different from your training MSLDv2) — check if there's a newer version with different patients

**Why:** This directly addresses Limitation #5 and is the single most impactful change you can make. Going from 1 → 2 external datasets changes the claim from "generalizes to one dataset" to "generalizes across sources."

### 2. Run 3 random seeds for the main CV experiment (Table 1)
Currently all experiments use seed=42. Running seeds 42, 123, 2024 for the main 5-fold CV (Table 1, `tab:main_cv`) would let you report mean ± std across both folds AND seeds. This addresses Limitation #7.

**Why:** A Q1 reviewer in medical imaging will almost certainly flag single-seed as a weakness. Even if you can't run 3 seeds for ALL experiments, doing it for the main table (4 settings × 5 folds × 3 seeds = 60 runs) is feasible on an A100 and would dramatically strengthen the paper.

### 3. Re-run ConvNeXtV2-Tiny (plain) baseline with the full phased training protocol
Your architecture ablation shows the plain ConvNeXtV2-Tiny nearly matches PoxCSAF-Net (0.922 vs 0.925 F1). A reviewer will ask: "Is the gap just the training protocol?" Re-running the closest competitor with the full 3-phase SAM+SWA protocol would neutralize this.

**Why:** This addresses Limitation #3 and is the difference between "our architecture helps" and "our training recipe helps." If the plain ConvNeXtV2-Tiny with full protocol still matches PoxCSAF-Net, you should honestly reframe the contribution as "identifying ConvNeXtV2 as the optimal backbone for federated pox classification" rather than claiming the custom modules are essential.

---

## Tier 2 — Medium Impact (would strengthen specific sections)

### 4. Evaluate FedPer per-client (not just aggregated)
Currently FedPer is evaluated on the aggregated test set, which is not the natural setting for personalized FL. Running per-client evaluation would let you show whether personalization helps individual clients even if the aggregate doesn't improve.

**Why:** This addresses Limitation #6. A FL expert reviewer will catch this immediately. If per-client results show FedPer winning on small clients (Client 1 with 10% data), that's a meaningful finding.

### 5. Add a dataset size justification paragraph in the Methods section
1,463 images is small. You should proactively justify this with:
- Comparison to similar published Q1 papers (e.g., "Ali et al. achieved Q1 publication with 1,002 images in Computers in Biology and Medicine")
- Note that the 4-class problem with focal loss + augmentation is designed for this scale
- Emphasize that the FL + DP-SGD + poisoning combination is the novelty, not the dataset size

**Why:** Preempting the reviewer's #1 objection is better than waiting for it in review.

### 6. Resolve `\cite{CITATION_NEEDED_wilcoxon}` and `\cite{CITATION_NEEDED_saerens}`
These must be replaced before submission. Specific references:
- **Wilcoxon**: Wilcoxon, F. (1945). Individual comparisons by ranking methods. *Biometrics Bulletin*, 1(6), 80–83.
- **Saerens**: Saerens, M., Latinne, P., & Decaestecker, C. (2002). Adjusting the outputs of a classifier to new a priori probabilities. *Pattern Recognition*, 35(1), 213–221.

---

## Tier 3 — Low Impact / Nice to Have

### 7. Add a t-SNE/UMAP visualization of the learned feature space
Show the 4-class embedding space for Fold 1, colored by class. This is a common figure in medical imaging Q1 papers and visually demonstrates separability.

### 8. Report confidence intervals (Wilson or bootstrap) for all main table values
Currently you report mean ± std. Adding 95% CIs (e.g., via bootstrap) would be more rigorous and is increasingly expected in Q1 medical AI venues.

### 9. Add a computational cost / carbon footprint table
Report total GPU-hours, CO2 estimate, and parameter count. This is increasingly expected in Q1 venues (especially Elsevier) and is easy to add.

### 10. Consider merging Discussion + Limitations
Currently the Limitations section reads like a checklist. Weaving limitations into the Discussion narrative (as "However, ..." sentences) reads more naturally and is preferred by Q1 reviewers.

---

## Summary: Realistic Path to Q1 Accept

| Action | Effort | Impact on Q1 odds |
|--------|--------|-------------------|
| Add 1 more external dataset | Medium (1-2 days) | ⭐⭐⭐⭐⭐ |
| 3 seeds for main CV | Medium (1-2 days on A100) | ⭐⭐⭐⭐ |
| Re-run ConvNeXtV2-Tiny with full protocol | Low (hours) | ⭐⭐⭐⭐ |
| FedPer per-client eval | Low (hours) | ⭐⭐⭐ |
| Resolve citation placeholders | Trivial | ⭐⭐⭐ |
| Dataset size justification paragraph | Low | ⭐⭐ |
| t-SNE figure | Low | ⭐⭐ |
| Bootstrap CIs | Low | ⭐⭐ |
| Carbon footprint table | Trivial | ⭐ |

**My recommendation:** Do items 1-4 + 6. That moves the paper from "borderline" to "likely accept" at **Computers in Biology and Medicine** or **Expert Systems with Applications**. If you also do item 2 (3 seeds), it becomes competitive at **IEEE JBHI**.
